Press Releases
Stay informed about Unravel Genomics research, partnerships, and progress.
Latest announcements
May 15
2026
The Phase 1 ENDORSE trial (NCT07590583) opened May 15, 2026 at City of Hope, evaluating Unravel's Endorse bx biology-guided therapy report to help physicians select treatment for hormone receptor-positive advanced or metastatic breast cancer after progression on first-line endocrine therapy.
Apr 8
2026
The Phase 2 IMMUNO-BIOMAP trial (NCT07288034) opened April 8, 2026 and is recruiting at City of Hope and partner sites, using blood- and tissue-based biomarkers and ctDNA to predict first-line PD(L)1 immunotherapy response and guide second-line treatment in stage IIIB–IV non-small cell lung cancer.
Feb 16
2026
The Phase 2 EVOLVE-BDT trial (NCT07340541) opened February 16, 2026 and is recruiting through the Translational Breast Cancer Research Consortium, using biomarker-stratified second-line therapy and serial liquid biopsies for ER+/HER2- and triple-negative metastatic breast cancer.